Targovax is a clinical stage immuno-oncology company developing immune activators for combination therapy in cancer. Targovax has a diversified immune activator portfolio and aims to become a leader in this area. The Company’s lead product, ONCOS-102, is an oncolytic adenovirus armed with an immune-stimulating transgene, which is currently being investigated in four ongoing clinical trials.
IR Contact
News
-
September 16, 2021Targovax ASA: Poster at European Society for Medical Oncology (ESMO)
-
August 27, 2021Targovax ASA: Abstract on ONCOS-102 phase 1 trial in advanced PD1 refractory melanoma is accepted at ESMO Congress
-
August 18, 2021Targovax ASA: second quarter and first half year 2021 results
-
August 16, 2021Targovax to present at upcoming scientific conferences
Q2 Second quarter 2021
Targovax ASA announced its second quarter 2021 results on Wednesday August 18, 2021.